OneVentures team ‘charmed’ by Queensland Health-IT company Media ReleaseCarolyn MillerApril 11, 2013Charm Health, Anne-Marie Birkill
Hatchtech publish data on Head Lice treatment safety study and mechanism of action Media ReleaseCarolyn MillerNovember 27, 2012Hatchtech, Paul Kelly
Vaxxas Appoints David Hoey as Company's First CEO Media ReleaseCarolyn MillerOctober 9, 2012Vaxxas, Paul Kelly
Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation Media ReleaseCarolyn MillerOctober 9, 2012Paul Kelly, Vaxxas
Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™ Media ReleaseCarolyn MillerSeptember 4, 2012Hatchtech, Paul Kelly
Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards Awards, Media ReleaseCarolyn MillerApril 17, 2012Vaxxas, OneVentures, Paul Kelly
Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial Media ReleaseCarolyn MillerOctober 26, 2010Hatchtech, Paul Kelly
